Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615906 | 0.96 | TLR7 (0.89) | TLR7TLR8 | |
| SCHEMBL1951699 | 0.94 | TLR7 (0.93) | TLR7TLR8 | |
| SCHEMBL6053125 | 0.93 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL5122398 | 0.91 | TLR7 (0.91) | TLR7TLR8 | |
| SCHEMBL1615627 | 0.91 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL18587594 | 0.90 | TLR7 (0.75) | TLR7TLR8 | |
| SCHEMBL3863599 | 0.90 | TLR7 (0.98) | TLR7TLR8 | |
| SCHEMBL3970764 | 0.90 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL5352948 | 0.88 | TLR7 (0.72) | TLR7TLR8 | |
| SCHEMBL5618407 | 0.88 | TLR7 (0.72) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344622-B1 | GUANIDINE SUBSTITUTED, FUSED 1H-IMIDAZO[4,5-C]PYRIDINE COMPOUNDS USEFUL IN THE TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES CO (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-108026092-B | Guanidine-substituted imidazo [4,5-c ] ring compounds | 3M创新有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | 3M INNOVATION PROPERTIES COMPANY (US) | 2019-11-26 | — | — | US | disclosed |
| US-20190055241-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2019-02-21 | — | — | US | disclosed |
| US-10150768-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180237435-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2018-08-23 | — | — | US | disclosed |
| EP-3344622-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c]RING COMPOUNDS | 3M Innovative Properties Company (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017040233-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-2507237-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068233-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136801-A1 | Novel Compounds | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10150768-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | IFNG, IL4, IRF3 | TLR7 55/4885TLR8 163/4885 |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | IFNG, IRF3, IL4 | TLR7 63/4885TLR8 211/4885 |
| US-20110136801-A1 | Novel Compounds | C1R, RB1, CNKSR1 | TLR7 3566/4885TLR8 4659/4885 |
| US-20190055241-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IRF3, IL4 | TLR7 63/4885TLR8 211/4885 |
| US-20180237435-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IL4, IRF3 | TLR7 55/4885TLR8 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.